The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani

BACKGROUND: New drugs are needed for leishmaniasis because current treatments such as pentavalent antimonials are toxic and require prolonged administration, leading to poor patient compliance. Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/Th2 responses and has the potentia...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Infect Dis
Main Authors: Varikuti, Sanjay, Volpedo, Greta, Saljoughian, Noushin, Hamza, Omar M, Halsey, Gregory, Ryan, Nathan M, Sedmak, Bren E, Seidler, Gabriella R, Papenfuss, Tracey L, Oghumu, Steve, Satoskar, Abhay R
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Major Articles and Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784510/
https://ncbi.nlm.nih.gov/pubmed/30239895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy552
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares